Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC By Ogkologos - July 27, 2026 59 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ELEVATE study Source RELATED ARTICLESMORE FROM AUTHOR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and... June 3, 2025 Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... April 16, 2025 Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... May 5, 2020 EMA Recommends Granting a Marketing Authorisation for Lurbinectedin April 30, 2026 Load more HOT NEWS What is Mindfulness? Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... First immunotherapy approved for cervical cancer in England and Scotland Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell...
